논문검색
Author Chien Ter Hsing, M.D.1, Sung Yong Oh, M.D.1, Suee Lee, M.D.1, Hyuk-Chan Kwon, M.D.1, Sung-Hyun Kim, M.D.1, Tae-Ho Park, M.D.1, Jong Soo Woo, M.D.2, Seo Hee Na, M.D.3 and Hyo-Jin Kim, M.D.1
Place of duty Departments of 1Internal Medicine, 2Thoracic and Cardiovascular Surgery and 3Pathology, Dong-A University College of Medicine, Busan, Korea
Title Extraskeletal Mesenchymal Chondrosarcoma of the Heart Responded to Systemic Chemotherapy: A Case Report
Publicationinfo Cancer Res Treat 2007 Sep; 039(03): 131-133.
Key_word Mesenchymal chondrosarcoma, Extraskeletal, Heart
Full-Text
Abstract Mesenchymal chondrosarcoma is a rare cartilaginous neoplasm of an extraskeletal origin, and this predominately occurs in the head and neck, and also in the lower extremities. Fewer than twenty cases of cardiac mesenchymal chondrosarcoma have so far been reported on. For the most part, the results of treatment for patients with this condition have been dismal. In this study, we describe a case of cardiac mesenchymal chondrosarcoma that responded to chemotherapy following surgical biopsy. A 46-year-old man was referred for evaluation of his pleural effusions in both lungs. Chest computed tomography revealed an ovoid-shaped mass in the posterior wall of the patient’s left atrium. The echocardiogram revealed a large ovoid-shaped immobile mass (11×6 cm2) in the pericardiac space, which was attached to the posterior wall of the left atrium. Emergency pericardiostomy with closure thoracostomy was performed. Seven days later, a thoracotomy was performed for reduction and diagnosis of the cardiac mass. The pathological diagnosis was extraskeletal mesenchymal chondrosarcoma of the heart.. Postoperative chemotherapy was performed for the huge remaining mass with a combined regimen of etoposide, ifosfamide and cisplatin. After 6 cycles, the patient showed a partial response without symptoms. Although cardiac mesenchymal chondrosarcoma has been reported to be chemotherapy- resistant with a short survival duration, chemotherapy may prove to be an effective treatment modality. (Cancer Res Treat. 2007;39:131-133)
출판정보 대한암학회지 2007 Sep; 039(03): 131-133.